Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138397 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL3143152 | 0.69 | KDM4E (0.39) | SMN1; SMN2 | |
| SCHEMBL3133818 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1441598 | 0.62 | — | — | |
| SCHEMBL2478278 | 0.59 | — | — | |
| SCHEMBL18096141 | 0.58 | SMN1; SMN2 (0.52) | SMN1; SMN2 | |
| SCHEMBL7788279 | 0.56 | — | — | |
| SCHEMBL7788282 | 0.56 | — | — | |
| SCHEMBL1499936 | 0.56 | OR51E2 (0.42) | SMN1; SMN2 | |
| SCHEMBL20424079 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | SMN1; SMN2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.